Literature DB >> 350633

Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis.

K Fuxe, B B Fredholm, S O Ogren, L F Agnati, T Hökfelt, J A Gustafsson.   

Abstract

The effects of ergot drugs on central monoaminergic mechanisms, particularly dopaminergic mechanisms, have been investigated in histochemical, biochemical and behavioral studies. It is concluded that the behavioral effects and the antiparkinsonian properties of ergot drugs can to a large extent be explained by the hypothesis that ergot drugs act at various dopamine receptor sites in the brain as partial agonists, the ratio of agonist-antagonist activity varying from one dopamine receptor population to another.

Mesh:

Substances:

Year:  1978        PMID: 350633

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  14 in total

1.  Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats.

Authors:  R Pagliari; L Peyrin; O Crambes
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 2.  A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view.

Authors:  R Horowski
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

Review 3.  The motor effects of bromocriptine--a review.

Authors:  D M Jackson; O F Jenkins; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

4.  Neurogenic non-adrenergic cutaneous vasodilatation elicited by hypothalamic thermal stimulation in dogs.

Authors:  W Peter; W Riedel
Journal:  Pflugers Arch       Date:  1982-11-01       Impact factor: 3.657

5.  Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine.

Authors:  D M Jackson; L P Martin; L G Larsson; R F Cox; B L Waszczak; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

6.  Treatment of Schizophrenia with ergot derivatives.

Authors:  C A Tamminga; M H Schaffer
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

7.  Binding of antiparkinsonian ergot derivatives to the dopamine receptor.

Authors:  R L Weir; R E Hruska; E K Silbergeld
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  Behavioural supersensitivity following neonatal 6-hydroxydopamine: attenuation by MK-801.

Authors:  T Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

9.  Effect of non-catecholic 2-aminotetralin derivatives on dopamine metabolism in the rat striatum.

Authors:  M G Feenstra; H Rollema; D Dijkstra; C J Grol; A S Horn; B H Westerink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-09       Impact factor: 3.000

10.  Bromocriptine-induced locomotor stimulation in mice is modulated by dopamine D-1 receptors.

Authors:  D M Jackson; M Hashizume
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.